Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alexion
Pharma
AZ touts Ultomiris results in post-transplant complication trial
Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug to make its mark.
Fraiser Kansteiner
Jun 16, 2025 10:32am
Syntimmune shareholders win again over AZ, this time for $181M
Jun 12, 2025 11:40am
Health plan sues AZ's Alexion over 'fraudulent' Soliris patents
Apr 17, 2025 10:50am
Arrowhead, Zevra fire up campaigns for Rare Disease Day 2025
Feb 28, 2025 10:18am
AZ slashes CEO Pascal Soriot's pay by 16% to $18.5M in 2024
Feb 19, 2025 8:20am
AZ loses $130M to Syntimmune shareholders in post-merger suit
Sep 9, 2024 11:43am